TCA
NVAX icon

Transcend Capital Advisors’s Novavax NVAX Stock Holding History

Transcend Capital Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,118
Closed -$212K – 510
2022
Q2 		$212K Buy
+4,118
New +$213K 0.02% 445
2022
Q1 		– Sell
-2,223
Closed -$318K – 536
2021
Q4 		$318K Buy
2,223
+588
+36% +$101K 0.03% 379
2021
Q3 		$221K Sell
1,635
-305
-16% -$67.2K 0.02% 435
2021
Q2 		$412K Sell
1,940
-95
-5% -$17.4K 0.06% 222
2021
Q1 		$369K Sell
2,035
-660
-24% -$132K 0.04% 283
2020
Q4 		$301K Buy
+2,695
New +$286K 0.04% 293

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Transcend Capital Advisors's NVAX Position: Q3 2022 in Review

Transcend Capital Advisors sold out of Novavax (NVAX) in Q3 2022, closing a stake of 4,118 shares — an estimated $212K sold.

Transcend Capital Advisors first reported a position in NVAX in Q4 2020 and held it in 6 quarters. The position peaked at $412K in Q2 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • Transcend Capital Advisors reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • Transcend Capital Advisors sold 4,118 Novavax shares in Q3 2022, an estimated $212K.
  • Transcend Capital Advisors first reported a position in Novavax in Q4 2020 and held it in 6 quarters.
  • Transcend Capital Advisors's Novavax position peaked at $412K in Q2 2021.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Transcend Capital Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.